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Abstract
A liver-humanized mouse model for CPS1-deficiency was generated by the high-
level repopulation of the mouse liver with CPS1-deficient human hepatocytes.
When compared with mice that are highly repopulated with CPS1-proficient
human hepatocytes, mice that are repopulated with CPS1-deficient human hepato-
cytes exhibited characteristic symptoms of human CPS1 deficiency including an
80% reduction in CPS1 metabolic activity, delayed clearance of an ammonium
chloride infusion, elevated glutamine and glutamate levels, and impaired metabo-
lism of [15N]ammonium chloride into urea, with no other obvious phenotypic dif-
ferences. Because most metabolic liver diseases result from mutations that alter
critical pathways in hepatocytes, a model that incorporates actual disease-affected,
mutant human hepatocytes is useful for the investigation of the molecular, bio-
chemical, and phenotypic differences induced by that mutation. The model is also
expected to be useful for investigations of modified RNA, gene, and cellular and
small molecule therapies for CPS1-deficiency. Liver-humanized models for this
and other monogenic liver diseases afford the ability to assess the therapy on actual
disease-affected human hepatocytes, in vivo, for long periods of time and will pro-
vide data that are highly relevant for investigations of the safety and efficacy of
gene-editing technologies directed to human hepatocytes and the translation of
gene-editing technology to the clinic.
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1 | INTRODUCTION
Excess nitrogen in the form of ammonia is accumulated
during the breakdown of proteins and amino acids. The
urea cycle is a pathway that predominantly occurs in liver
to eliminate excess ammonia in the blood by converting it
into urea, which is excreted in urine, but unlike ammonia is
non-toxic. Six separate enzymes comprise the functional
urea cycle, N-acetylglutamate synthase, carbamoyl phos-
phate synthetase I, ornithine transcarbamylase (OTC),
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argininosuccinate synthetase, argininosuccinate lyase, and
arginase and the two transporters ORNT1 (or SLC25A15)
and citrin, or aspartate-glutamate carrier (SLC25A13).
Mutations in any of the urea cycle genes or of the two-inner
mitochondrial membrane transport proteins can result in a
urea cycle defect (UCD).16,20,28,32
A rare autosomal recessively inherited metabolic disor-
der, CPS1-deficiency (CPS1-D) results from a partial or
complete loss of CPS1 activity, the first committed enzyme
in the urea cycle. Patients deficient in CPS1 activity are fre-
quently healthy at birth but within 24 to 72 hours, will
exhibit more serious symptoms, including elevated blood
ammonia, lethargy, and vomiting.16,23 However, less severe
conditions may present later in life. The incidence of
CPS1-D is estimated to be 1 to 9 in 1 000 000 (https://www.
orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&Expert=
147) and 1 in 1 300 000 live births in the United States.33
More than 262 CPS1-D–associated genetic variants have
been identified.9,15 If undiagnosed or untreated, the resultant
hyperammonemia can lead to life-threatening encephalopa-
thy and coma.3,5,21,23,35 Severe hyperammonemic episodes
can result in irreversible neurological damage. The mecha-
nisms of neurological injury includes neurotransmitter
abnormalities and cerebral edema due to accumulation of
glutamine which is osmotically active.
Currently, there is no cure for CPS1-D other than
orthotopic liver transplantation. However, due to a limited
availability of donor organs, all patients who might require a
liver transplant may not receive one.22 The scarcity of organ
donors has initiated a search for alternative treatments for
UCD patients4,6,35,38 including human hepatocyte
transplantation.26,30
Animal models are of undeniable importance to study
pathophysiological aspects of human diseases and to validate
treatments. Current murine models available for each UCD
have shown both advantages and disadvantages.7,8,27–29
A CPS1 knockout mouse was generated, and while it recapit-
ulates aspects of the human disease phenotype, including
severe hyperammonemia, all affected mice died within
36 hours of birth, making it difficult to study or treat the dis-
ease or even to maintain the animal model.28 The original
CPS1 gene knockout mouse model may no longer exist.7
A more recent study reported the conditional disruption of the
CPS1 gene in mice that survived only for 4 weeks and pro-
vided a phenotype with hyperammonemia but without orotic
aciduria .19 In addition, rodent models have disadvantages,
particularly for investigating potential therapies, because there
are differences in the immune system, drug metabolism,
DNA synthesis and repair pathways, and other biochemical
processes between mice and humans that can make extrapola-
tion of the data from animal studies to human patients chal-
lenging. Because most metabolic liver diseases result from
mutations that alter a specific function or functions of paren-
chymal hepatocytes, a hypothesis was generated that a useful
model for a human metabolic liver disease would be one that
incorporated actual, disease-affected human hepatocytes. An
improvement to the model could be realized if studies of the
disease-affected human hepatocytes could be conducted,
in vivo.
We and others have generated chimeric mice where
mouse hepatocytes can be almost completely replaced with
human hepatocytes.2,10,13,14,17,25,31,34,36 Successful
repopulation of the liver with hepatocytes requires a mouse
model that allows engraftment of donor cells, avoids rejec-
tion of the cellular xenograft, and also provides a selective
growth advantage to the donor cells. The model reported
here, utilized triple knockout mice, the so-called FRGN
mice, where the fumarylacetoacetate hydrolase (Fah),
recombination activating 2 gene (Rag2), and the common
gamma chain of interleukin 2 receptor (IL2rg) genes were
knocked out,2 and mice were subsequently cross-bred with
non-obese diabetic (NOD) mice.36 Mice were rendered
severely immunodeficient, so that they would not reject the
human xenograft, by knocking out the Rag2 and IL2rg
genes. Fah-deficient mice are the murine equivalent of the
human liver disease hereditary tyrosinemia type 1 (HT-1).
The Fah deficiency in the mouse hepatocytes creates a
mechanism to provide a growth advantage to the
transplanted human hepatocytes. In HT-1 patients, the
severe liver disease can be prevented by providing a
protective drug, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,
3-cyclohexanedione (NTBC). In the mouse model, when
NTBC is withdrawn, toxic tyrosine metabolites accumulate
and severely injure the Fah-deficient mouse hepatocytes
creating a strong liver regeneration stimulus. During this
time, if FAH-proficient human hepatocytes are
transplanted, they can survive in the absence of NTBC and
respond to the signals for liver regeneration and highly
repopulate the mouse liver, frequently replacing more than
90% of the mouse hepatocytes. In the present study, chime-
ric mice were generated by the transplantation of human
hepatocytes from normal donors as well as from a patient
with CPS1-D, and the resulting phenotypes were
investigated.
2 | MATERIALS AND METHODS
2.1 | FRGN mice
All institutional and national guidelines for the care and use
of laboratory animals were followed. All animal studies are
conducted according to Karolinska Institutet guidelines and
under approved ethical protocol ID400 42-17. FRGN mice
were generated by knocking out Fah, Rag2, and IL2rg, the
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so-called FRG mouse, and cross-breeding with NOD
mice.2,36 The FRGN mouse does not develop diabetes
because they cannot mount a sufficient immune response.
Mice used for this study were between 5 and 6 weeks old,
originally obtained from Yecuris Corporation (Tualatin, Ore-
gon) and maintained in breeding colonies at Karolinska
Institutet Animal Facility. Mice were maintained throughout
the study on PicoLab High Energy Mouse Diet with 18.9%
protein (Animal Specialties and Provisions, Quakertown,
Pennsylvania) and supplemented with NTBC to avoid lethal
liver damage. After cell transplantation, animals were cycled
on-and-off of NTBC to support engraftment and the prolifer-
ation of donor-human hepatocytes. All animals that achieved
4 mg/mL of circulating human albumin were used in
the study.
2.2 | Cell preparation
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000 to 2005. Informed
consent was obtained from all patients before being included
in the study. Human hepatocytes were procured from donor
liver tissue according to ethical protocol (human studies:
2014/1561-32; animals ID 40042-17). Organ donors were
tested, and were negative, for hepatitis viruses B and C, and
human immunodeficiency virus. All human hepatocytes
were isolated as previously described.12 Normal
(CPS1-proficient) liver tissues were collected from a
50-year-old female, an 8-year-old male, a 6-year-old male,
and a 4-day-old female organ donor. The CPS1-D hepato-
cytes were isolated from the explanted liver of a 1.5-year-
old female who received an orthotopic liver transplant. All
cells were cryopreserved before transplantation in University
of Wisconsin solution (BEL GEN 1000, Lissieu, France)
supplemented with 10% dimethyl sulfoxide (DMSO; Sigma-
Aldrich, St. Louis, Missouri). Hepatocytes were thawed on
the day of transplantation in a 37C water bath until the ice
is barely visible and cells are diluted with 10 volumes of
cold Williams medium E with 10% calf serum and cen-
trifuged at 90g at 4C for 5 minutes. The cell pellet was
suspended in cold plasmalyte (Baxter, Norfolk, UK) for
transplantation. The viability for control and CPS1-D hepa-
tocytes was 72 ± 9% and 72 ± 5%, respectively, after
thawing for transplantation.
The two disease-causing variants identified in the
CPS1-D patient were c.2339G>A (p.Arg780His) on one
(maternal) allele and c.3559-745A>G on the other (paternal)
allele. The latter generates a new donor splice site causing
the insertion of an intronic region in the CPS1 mRNA
between exons 29 and 30. A truncated protein is produced
(p.Arg1186_Val1187insKPRLSK*), most likely non-func-
tional, due to a premature stop codon.
2.3 | Hepatocyte transplantation
The FRGN mice were pretreated approximately 24 hours
before transplantation with a adenovirus vector expressing
urokinase plasminogen activator (Yecuris Corp., Tualatin,
Oregon).2,36 Hepatocytes were injected directly into the
parenchyma of the spleen by making a small incision on the
left abdominal region and the organ was exposed. Each
mouse received one million viable hepatocytes suspended in
200 μL plasmalyte delivered over about a 1-minute period
with a syringe and a 29G needle. The spleen was returned to
the abdominal cavity, and the incision was sutured using
absorbable 5.0 vicryl suture (product no: V391H, Ethicon,
Diegen, Belgium). The mice were anesthetized during the
entire procedure with isoflurane (Baxter, Norfolk, UK).
Mice received appropriate analgesia at the time of surgery
and 24 hours after the surgical procedure.
2.4 | Blood sampling and ELISA
Starting from the fifth week after hepatocyte transplantation,
human albumin levels were monitored. Blood samples were
collected from mice twice a month. The mice were placed in
a restrainer, and blood samples were collected from the tail
vein using 27G needle. From each mouse, 2 μL blood was
collected, diluted in 198 μL diluent, and assayed using the
Quantitative Human Albumin ELISA Quantitation Kit
(Bethyl Laboratory, Montgomery, Texas) according to the
manufacturer's protocol. Multiple measurements were per-
formed on each sample, at different dilutions
(1:100-100 000), to quantify the level of “humanization”. It
is estimated that 1 mg/mL of circulating human albumin rep-
resents a 20% level of repopulation with human hepato-
cytes.2,36 A fresh standard curve (ranging from 15 to
200 ng/mL) made with human reference serum RS10-110-4
(Bethyl laboratory Inc.) was included in each analysis.
2.5 | Ammonia measurement and ureagenesis
Ammonia levels were measured by taking 5 μL of blood
diluted in 20 μL of water. Samples were analyzed immedi-
ately using an Arkray pocket chem (Arkray, AT, Nether-
lands) according the manufacturer's instructions.
Ureagenesis assay was performed on animals rep-
opulated with human hepatocytes to an estimated level of
80% or higher, or > 4 mg/mL of circulating human albu-
min. Enrichment of urea from [15N]-labeled ammonia
was measured following an intraperitoneal injection of
[15N]ammonium chloride (product number 299251,
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>99% pure, Sigma-Aldrich) 4 mmol/kg of body weight,
dissolved in 1 × phosphate-buffered saline, as originally
described by Yudkoff et al39 and modified by Allegri
et al.1 Mice were off of NTBC a minimum of 4 days
before the assay. Samples for the ureagenesis assay were
collected pre, and 30 minutes post, injection of [15N]
ammonium chloride where 5 μL of blood was diluted
with 100 μL of water and frozen immediately. Alterna-
tively, 5 μL of blood was added to a filter paper (IDBS-
226; Perkin Elmer, Shelton, CT) and stored at −20C in a
sealed bag containing desiccant and analyzed as
described by Allegri et al.1
2.6 | Amino acid detection and CPS1 and
OTC enzyme assays
Amino acid analysis was performed in the clinical labora-
tory from dried blood spots using tandem MS. CPS1 and
OTC assays were performed according to Gautschi et al.11
In summary, the frozen and pulverized liver samples were
homogenized on ice with a glass Teflon homogenizer.
Enzyme activities were determined in duplicates at 37C,
with liver homogenates diluted with water, 1:100 for the
OTC and 1:300 for CPS1 measurements. For OTC activity,
300 μL of ornithine (2.5 mM) and carbamoylphosphate
(5 mM), were added to the 25 μL diluted homogenate. The
reaction was stopped after 10 minutes by addition of
300 μL 5% trichloroacetic acid and 0.5% phosphotungstic
acid. The reaction product, citrulline, was measured spec-
trophotometrically at 464 nm after reaction with
diacetylmonoxime, antipyrine, Fe and quantified using a
citrulline standard curve. CPS1 activities were measured as
a coupled reaction with addition of excess OTC. In sum-
mary, 150 μL of reaction solution containing ammonium
hydrogen carbonate (109 mM), N-acetylglutamate
(10 mM), ornithine (7 mM), magnesium sulfate (20 mM),
and ATP (24 mM) were incubated for 15 minutes with
25 μL of liver homogenate and stopped as above. The final
reaction product, citrulline, was quantified as described pre-
viously. Citrulline measurements were corrected for blank
reagents and endogenous citrulline (addition of stop solu-
tion before addition of homogenate). Protein concentrations
were determined with a Lowry test.
2.7 | Tissue collection and reverse
transcriptase polymerase chain reaction
Liver tissue was collected from mice repopulated with con-
trol or CPS1-D hepatocytes. Portions of each liver lobe
were fixed in formalin. Remaining liver tissue was crushed
to a powder in liquid nitrogen and mixed homogeneously
for molecular and enzymatic analysis. Tissue samples were
lysed in Trizoltm solution (Thermo Fisher, Waltham, Massa-
chusetts) and RNA isolated according to the manufacturer's
instructions. Total RNA was converted to complimentary
DNA using a high-capacity cDNA kit (Thermo Fisher, Illi-
nois). Gene expression was assessed using TaqMan assays
(Thermo Fisher) for CYP3A4 (Hs00430021_m1), CYP1A2
(Hs01070374_m1), CYP2B6 (Hs03044634_m1), UGT1A6
(Hs01592477_m1), CPS1 (Hs00157048_m1), FAH
(Hs00908445_m1), OTC (Hs00166892_m1), ALB
(Hs00609411_m1), and A1AT (Hs01097800_m1). The Ct
values were normalized to the house keeping gene
cyclophilin A (PPIA) (Hs99999904_m1). All assays were
conducted with TaqMan primers that are specific for the
human genes and do not cross react with the mouse homo-
logs. Nontransplanted FRGN mouse liver tissue was used
as a negative control, and the expression of all genes
reported here was undetectable in untransplanted FRGN
mouse liver tissue.
2.8 | Statistical analysis
Results are expressed as individual values and as Box and
Whisker plots showing median, 25- and 75-percentiles. Data
sets were compared by Mann-Whitney nonparametric tests,
because the data were not normally distributed. P-value
<0.05 was considered as significant (*P < 0.05; **P <
0.001; ***P < 0.0001). Data were analyzed with GraphPad
Prism software, version 6 (GraphPad Software Inc., San
Diego, California).
3 | RESULTS
3.1 | Human album levels in liver-
humanized mice
Human albumin was detected in the blood of transplanted
mice, indicating that the human hepatocytes engrafted and
proliferated post-transplant. All animals that achieved a min-
imum of 4 mg/mL of human albumin,estimated to be ~80%
repopulation were used for the subsequent study. There was
no statistical difference between the level of human albumin
in mice that were transplanted with control or CPS1-D
human hepatocytes (Figure 1).
3.2 | Blood ammonia and ureagenesis
Mice repopulated with CPS1-D hepatocytes showed a
numerically higher basal blood ammonia of 182 μM as com-
pared with 148 μM in control animals that received CPS1
proficient hepatocytes (Figure 2A); however, this difference
did not reach statistical significance. Mice were examined
for their ability to metabolize ammonia and to synthesize
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urea from exogenous [15N]ammonium chloride. As shown
in Figure 2B, the control mice maintained significantly
lower ammonia levels post injection with a median of
494 μM while CPS1-D mice displayed impaired clearance
of ammonia from the blood with a median blood ammonia
of 818 μM (Figure 2).
The percentage of enrichment of [15N] into urea follow-
ing the infusion of a [15N]H4Cl bolus is a measure of
ureagenesis after a 30 minutes period. As shown in Figure 3,
there was a significant difference between mice liver-
humanized with healthy control (11% enrichment) as com-
pared with those repopulated with the CPS1-D hepatocytes
(7% enrichment; Figure 3).
As compared with control animals, mice repopulated
with CPS1-D human hepatocytes showed a different
response to the ammonium infusion. At post injection,
CPS1-D mice most became lethargic. Their reaction time to
a startle or an attempt to pick them up was obviously
impaired. Mice repopulated with control human hepatocytes
displayed normal behavior through the 30-minute observa-
tion period.
3.3 | Blood amino acid levels
The blood samples were collected from mice repopulated
with control or CPS1-D human hepatocytes for amino acid
quantification. In the standard analysis performed on blood,
18 different amino acids were analyzed including citrulline,
arginine, alanine, glutamine, and glutamate. Only the blood
levels of glutamine and glutamate were statistically different
between control and CPS1-D mice. Both glutamine and glu-
tamate levels were significantly increased in CPS1-D mice
when compared with control mice (Figure 4A,B). Median
glutamine levels in control and CPS1-D mice were 390 and
547 μM, respectively. Median glutamate levels in control
and CPS1-D were 261 and 318 μM, respectively.
3.4 | CPS1 and OTC enzyme activity
Enzyme analyses to quantify OTC and CPS1 metabolic
activities were performed on liver tissue from mice selected
at random from animals highly repopulated with control or
CPS1-D hepatocytes (Figure 5). There was a significant dif-
ference in the levels of CPS1 activity in CPS1-D mice as
compared with those that were highly repopulated with con-
trol human hepatocytes. The liver of the CPS1-D mice
expressed approximately 20% of the CPS1 activity measured
in control mice (Figure 5A). A second urea cycle enzyme,
OTC activity was also measured in samples from the same
liver, but there was no significant difference between OTC
activities in the liver of CPS1-D and control mice.
FIGURE 1 Circulating human albumin levels in mice
transplanted with control and CPS1-deficiency (CPS1-D) human
hepatocytes. The extent of repopulation of the mouse liver is estimated
in live mice by the levels of circulating human albumin. There was no
significant difference in level of human albumin between control and
CPS1-D mice. The number of highly repopulated mice analyzed with
CPS1-D (n = 33) or control human hepatocytes (n = 35) are shown as
individual dots
FIGURE 2 Blood ammonia levels in liver-humanized mice. Ammonia levels in the blood of control and CPS1-D liver-humanized mice were
measured before (basal, 2A) and 30 min post, (2B) an [15N]ammonium chloride infusion as described in the Methods. The median basal ammonia
levels were not significantly higher in the CPS1-D group as compared to control, 148 μM and 182 μM for control and CPS1-D animals,
respectively. Blood ammonia levels were significantly higher 30 min post-injection of ammonium chloride in the CPS1-D group as compared to
controls, 494 μM and 818 μM for control and CPS1-D animals, respectively. ns, not significantly different; ****, significantly different, p<0.001
1058 SRINIVASAN ET AL.
3.5 | Mature liver gene expression in liver-
humanized mice
Given the large differences in CPS1 activity observed in the
CPS1-proficient and deficient livers, the expression of sev-
eral mature liver genes was analyzed in the liver samples to
determine if other metabolic pathways were altered in the
CPS1-D mice. Gene expression was determined using quan-
titative, reverse-transcription polymerase chain reaction and
normalized to human cyclophilin A. The analysis included
the genes for the enzymes that metabolize a major propor-
tion of the Food and Drug Administration–approved drugs,
the Cytochromes P450 in the 1A, the 2B, and the 3A family
(CYP1A2, CYP2B6, and CYP3A4), and uridine diphos-
phate glucuronosyltransferase (UGT)1A6, an enzyme highly
expressed in human liver and required for the excretion and
elimination of many drugs and endogenous compounds from
the body. In addition, analysis of genes was included that
when mutated can create other liver-based diseases, that is,
CPS1, FAH, OTC, and alpha 1 antitrypsin (A1AT; Figure 6).
These genes were chosen because they are regulators of crit-
ical physiological processes in the normal human liver and
the expression of each gene can vary greatly between indi-
viduals. Because of this variability, differences between the
expression of these genes in mice humanized with cells from
normal donors and the CPS1 donor would be more obvious.
No other genes were analyzed, and as shown in Figure 6,
there were no significant differences in the expression of
these various liver genes between the two groups.
FIGURE 4 Glutamine and glutamate concentrations in control and CPS1-D mice. Blood glutamine (4A) and glutamate (4B) concentrations
were analyzed as described in Methods. The glutamine levels were 390 μM and 547 μM for control and CPS1-deficient animals and the glutamate
levels were 261 μM and 318 μM, respectively. Both glutamine (***p<0.001) and glutamate (*p<0.05) levels were significantly higher in the CPS1-
D animals as compared to control animals
FIGURE 3 Isotopic enrichment of [15N] ammonia into urea in
control and CPS1-deficiency (CPS1-D) mice. The incorporation of
[15N]ammonium into urea in the blood after 30 minutes post injection
of [15N] ammonium chloride (4 mmol/kg). The enrichment [15N] into
urea was significantly different between control (11%) and
CPS1-deficient animals (7%) (P < 0.001)
FIGURE 5 CPS1 and OTC metabolic activity in control and CPS1-D mice. The enzymatic activity of CPS1 (5A) and OTC (5B) in liver-
humanized mice was measured as described in Methods. Mean CPS1 activities were significantly lower (**p<0.01) in CPS1-D mice as compared to
controls, 55±24 mU/mg protein and 11±2 mU/mg protein for control and CPS1-D animals, respectively. There was no significant difference in the
OTC activities between the two groups, with 924±434 mU/mg and 752±227 mU/mg protein for control and CPS1-D animals, respectively
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4 | DISCUSSION
Investigations of xenobiotic metabolism have revealed con-
siderable species differences between rodents and human
patients with respect to the uptake, metabolism and excretion
of drugs. Perhaps one of the most noteworthy examples was
Fialuridine, which showed little to no toxicity and great
potential for the treatment of HBV infection in preclinical
animal studies, but when the drug was provided to human
patients, it caused severe liver failure.24
Studies with liver-humanized mice were initiated in
efforts to make the extrapolation of preclinical studies more
likely to translate to the clinic.18,34,37 However, nearly all
publications describing liver-humanized mice restrict their
investigations to issues related to toxicology and drug
metabolism since these endpoints are critical to drug devel-
opment and are largely dependent on hepatocyte function.
Because most liver-based metabolic diseases result from
mutations in genes expressed in hepatocytes, a liver-
humanized mouse, made with human hepatocytes isolated
from a patient with a metabolic liver disease could be a use-
ful model to investigate the pathology, as well as the ther-
apy, of the disease. The FRG and the FRGN mouse models
were initially developed by Grompe et al.2 There was no evi-
dence of cell fusion of donor hepatocytes with mouse hepa-
tocytes in liver-humanized mice2 and mice became highly
repopulated with donor, human hepatocytes. This report
expands our previous studies where liver-humanization was
reported (but not characterized) with hepatocytes from sev-
eral monogenic liver diseases.13 This current report charac-
terizes the phenotype of mice that are highly repopulated
with human hepatocytes from a patient with severe CPS1-D,
in comparison with animals transplanted with normal human
hepatocytes. This model requires the transplantation and
proliferation of the normal or disease-affected hepatocytes in
each recipient mouse.
FIGURE 6 Quantitative
reverse transcriptase polymerase
chain reaction (RT-PCR) analysis
of cDNA made from mRNA
isolated from liver tissue from
control and CPS1-deficiency
(CPS1-D) mice. No statistically
significant difference in gene
expression was detected between
the two groups of animals
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When compared with mice transplanted with normal
human hepatocytes, the phenotype of mice transplanted with
CPS1-D hepatocytes was consistent with what is observed
in human patients. Mice repopulated with CPS1-D hepato-
cytes displayed elevated glutamate and glutamine levels on a
normal protein diet (18.9% protein) and higher blood ammo-
nia levels and delayed clearance of ammonia following an
[15N]ammonium chloride challenge. Ureagenesis, measured
as the enrichment of 15N into urea following the infusion of
[15N]H4Cl was significantly lower in the CPS1-D recipient
mice (Figure 3). The ureagenesis results are consistent with
the greatly reduced CPS1 enzyme activity measured in
CPS1-D mice, which was only 20% of the level measured in
mice transplanted with normal human hepatocytes
(Figure 5). As expected, the activity of another urea cycle
enzyme, OTC, was not significantly different between
CPS1-D and control mice.
Data in Figure 5 clearly show that while OTC activity is
normal, the CPS1 activity is greatly reduced. Given the
mutations identified in this CPS1-D patient, one could only
speculate on the likely presence of both CPS1-mRNA and
protein in the hepatocytes or the phenotypic changes that
might result. Only so much can be inferred from DNA
sequence alterations. This model allows the investigator to
fully interrogate the molecular, biological, and pathological
consequences that the mutation produces, in an in vivo
model. In addition to being a useful model to investigate
possible therapies for the disease, this liver-humanized
model allows detailed investigations of the molecular
changes as well as the pathology associated with that spe-
cific mutation in actual disease-affected human hepatocytes.
While CPS1 enzyme activity and function was reduced
in the CPS1-D mice, there is evidence that other liver func-
tions are maintained at normal levels, as was observed with
OTC activity. Circulating human albumin levels were not
significantly different between mice receiving normal human
hepatocytes and those that received CPS1-D hepatocytes
(Figure 1). In addition, 18 different amino acids were ana-
lyzed including citrulline, arginine, alanine, glutamine and
glutamate, and several additional amino acids. A statistical
analysis of the two groups only identified differences in the
levels of glutamine and glutamate. The data with glutamine
and glutamate are consistent with the CPS1-D phenotype
but the lack of differences in the other amino acids supports
a conclusion that other critical liver biochemical pathways
were not altered in these liver-humanized mice. In addition,
mRNA levels of nine hepatic genes expressed in mature
human liver failed to identify any significant differences
between the control and the CPS1-D mice. While not an
exhaustive investigation of liver function and gene expres-
sion, there were no obvious phenotypic or genetic
differences between the normal and the CPS1-D mice except
those attributable to the CPS1-D itself.
Human albumin in the recipient mice was used to esti-
mate the level of repopulation. Being conservative, and try-
ing to avoid the most severe symptoms of CPS1-D in
recipients, the study was conducted with mice that achieved
a minimum of 4 mg/mL human albumin, which is estimated
to correlate with ~80% level of repopulation with human
hepatocytes (1 mg/mL ’ 20% humanization). In some mice,
higher levels of repopulation with mutant human hepato-
cytes were likely achieved and mice became lethargic, failed
to eat, lost weight, and had to be treated with ammonia scav-
engers to restore health. All mice investigated here displayed
a high level of humanization as estimated from the circulat-
ing human albumin levels. The phenotype displayed in the
CPS1-D mice, particularly with respect to the basal level of
ammonia in the mice maintained on a regular protein diet
could be expected in mice that maintained residual 20% of
normal CPS1 activity and an 80% level of repopulation with
mutant human cells. A more severe phenotype can be
achieved in some mice at higher levels of repopulation with
mutant cells, however, at the expense of animal health and
welfare. At the level of humanization investigated here, the
CPS1-D phenotype is readily quantified with standard tests
in live animals. If a successful drug, genetic or cellular ther-
apy were provided, a normalization of the CPS1-D pheno-
type would likely be verifiable with this mouse model.
In summary, a liver-humanized mouse model for
CPS1-D was generated through the high-level repopulation
of the liver of mice with CPS1-D human hepatocytes. The
resultant mice exhibited characteristic symptoms of CPS1-D
with no other obvious phenotypic differences when com-
pared to mice transplanted with normal human hepatocytes.
It is likely that preclinical studies conducted with liver-
humanized mice will provide data more easily extrapolated
and relevant to human CPS1-D. Liver-humanized mice in
general are likely to be an important model to study small
molecule, cellular and gene therapies, and especially gene
correction technologies such as those mediated by CRISPR
or other gene-editing procedures. These state-of-the-art tech-
nologies require interaction with the human genome at pre-
cise sequences and the interplay of the human DNA
replication and repair pathways in the editing process, all of
which can differ greatly between mice and humans. It would
be advantageous to perform preclinical studies of gene-
editing and other newer technologies with human hepato-
cytes, and when possible, with the actual disease-affected
human hepatocytes. The value of the data obtained from
such studies will be greatly enhanced if those studies can be
conducted, in vivo. Studies with live animals will enable a
comprehensive assessment of the long-term outcomes of
these interventions. Following treated animals long-term will
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allow, not just an investigation of the phenotypic correction
of the disease, but other endpoints just as important such as
the long-term safety of the procedures. Perhaps these liver-
humanized models will be most informative for the investi-
gation of the safety and efficacy of gene-editing technologies
on human cells in vivo and the translation of the gene-
editing technologies to the clinics.
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